Efficacy and safety of TE regimen versus CEF regimen for Chinese women with TNM <b>Ⅱ</b>A to <b>Ⅲ</b>C stage breast cancer: a meta-analysis _Chinese Journal of Evidence-Based Medicine

Authors：

LIU Aijun , LU Liqing ,  ZHANG Jianping

College of Pharmacy, Jinan University, Guangzhou, 510632, P.R.China;

Corresponding author：

ZHANG Jianping, Email: tzhangjp@jnu.edu.cn

Keywords：

Breast cancer; Neoadjuvant chemotherapy; TE regimen; CEF regimen; Chinese women; Randomized controlled trial; Systematic review; Meta-analysis

DOI：

10.7507/1672-2531.201703123

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To systematically review the efficacy and safety of TE regimen versus CEF regimen for Chinese women with ⅡA to ⅢC stage breast cancer. Methods Databases including PubMed, EMbase, VIP, CNKI, WanFang Data and CBM were electronically searched from inception to December 2016 to collect randomized controlled trials (RCT) on TE regimen versus CEF regimen for Chinese women with ⅡA to ⅢC stage breast cancer. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of included studies. Then, meta-analysis was performed by using RevMan 5.3 software. Results A total of 14 RCTs were included. The results of meta-analysis showed that: the complete remission rate (CR) (RR=1.73, 95%CI 1.35 to 2.22, P<0.000 1) and clinical efficacy rate (RR) (RR=1.31, 95%CI 1.22 to 1.42,P<0.000 01) of the TE group were superior to those of the CEF group. But there were no significant differences between two groups in cardiac toxicity, myelosuppression and gastrointestinal reactions. Conclusions TE regimen is superior to CEF regimen in terms of efficacy for the Chinese women with ⅡA to ⅢC stage breast cancer, and there is no difference between the incidence of adverse reactions. Due to limited quality and quantity of the included studies, more high quality studies are required to verify above conclusions.

Citation： LIU Aijun, LU Liqing, ZHANG Jianping. Efficacy and safety of TE regimen versus CEF regimen for Chinese women with TNM ⅡA to ⅢC stage breast cancer: a meta-analysis . Chinese Journal of Evidence-Based Medicine, 2017, 17(12): 1413-1418. doi: 10.7507/1672-2531.201703123 Copy

1.	Frei E. Clinical cancer research: an embattled species. Cancer, 1982, 50(10): 1929-1992.
2.	唐利立, 张超杰, 刘少华, 等. 新辅助化疗对Ⅱ期和Ⅲ期乳腺癌的疗效观察. 中国肿瘤临床, 2005, 32(22): 1293-1295.
3.	满莉, 周立中, 董禹洋. 两种新辅助化疗方案治疗进展期乳腺癌的疗效对比研究. 中国肿瘤临床与康复, 2014, 21(3): 276-279.
4.	范扬航, 吴智勇, 黄建豪, 等. 多西他赛联合表柔比星新辅助化疗治疗局部晚期乳腺癌疗效观察. 广东医学, 2011, 32(8): 1059-1061.
5.	李冬云, 黄昌杰, 湛永滋, 等. 乳腺癌两种新辅助化疗方案的临床观察(附64例报告). 广西医学, 2012, 34 (9): 1215-1216.
6.	柴小郁. 新辅助化疗方案在乳腺癌治疗中的应用效果观察. 基层医学论坛, 2014,18(29): 3960-3961.
7.	聂红霞, 刘叶娟, 唐伟敬. 新辅助化疗方案在乳腺癌治疗中的应用效果观察. 当代医学, 2013, 19(5): 48-49.
8.	张莉. 新辅助化疗方案在乳腺癌治疗中的应用效果观察. 中外医学研究, 2014, 12(2): 116-117.
9.	陈丽娟. 新辅助化疗方案TE与FEC治疗局部晚期乳腺癌疗效观察. 中国医药指南, 2011, 9(28): 214-216.
10.	邹玉峰. 局部晚期乳腺癌新辅助化疗的研究. 中国当代医药, 2016, 23(32): 65-67.
11.	郑慧. 表阿霉素联合紫杉醇在局部晚期乳腺癌新辅助化疗治疗中的疗效评价. 中国实用医药, 2014, 9(21): 111-112.
12.	刘一范. 表阿霉素联合紫杉醇新辅助化疗治疗局部晚期乳腺癌疗效分析. 临床合理用药杂志, 2014, 7(19): 60-61.
13.	刘宏军, 杨德启, 曹迎明, 等. 不同新辅助化疗方案治疗乳腺癌的临床观察. 中国肿瘤临床, 2004, 31 (16): 31-34.
14.	贾琦. 两种新辅助化疗方案治疗乳腺癌的近期疗效和不良反应比较. 哈尔滨医药, 2012, 32(3): 196-197.
15.	王冰涛, 马向涛, 姚金华, 等. 术前ET与CEF新辅助化疗方案治疗乳腺癌的临床观察. 北京医学, 2007, 29(11): 658-660.
16.	韩瑜. 表阿霉素联合紫杉醇在局部晚期乳腺癌新辅助化疗治疗中的临床疗效分析. 中国伤残医学, 2013, 21(9): 162-163.
17.	Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol, 2005, 16(10): 1569-1583.
18.	陈灿铭, 沈坤炜, 吴炅, 等. 去甲长春花碱加表柔比星新辅助化疗方案治疗局部晚期乳腺癌的临床研究. 中国癌症杂志, 2003, 13(4): 28-31.
19.	Crown J, O'Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical. Oncologist, 2004, 9(Suppl 2): 24-32.
20.	Andrade JM, Carrara HH , Pimentel FF, et al. Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer. Med Oncol, 2011, 28(Suppl 1): 65-69.
21.	De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol, 2008, 26(1): 44-53.
22.	武阳. 表阿霉素联合紫杉醇在局部晚期乳腺癌新辅助化疗中的应用观察. 中国实用医药, 2014, 9(24): 155-156.

1. Frei E. Clinical cancer research: an embattled species. Cancer, 1982, 50(10): 1929-1992.
2. 唐利立, 张超杰, 刘少华, 等. 新辅助化疗对Ⅱ期和Ⅲ期乳腺癌的疗效观察. 中国肿瘤临床, 2005, 32(22): 1293-1295.
3. 满莉, 周立中, 董禹洋. 两种新辅助化疗方案治疗进展期乳腺癌的疗效对比研究. 中国肿瘤临床与康复, 2014, 21(3): 276-279.
4. 范扬航, 吴智勇, 黄建豪, 等. 多西他赛联合表柔比星新辅助化疗治疗局部晚期乳腺癌疗效观察. 广东医学, 2011, 32(8): 1059-1061.
5. 李冬云, 黄昌杰, 湛永滋, 等. 乳腺癌两种新辅助化疗方案的临床观察(附64例报告). 广西医学, 2012, 34 (9): 1215-1216.
6. 柴小郁. 新辅助化疗方案在乳腺癌治疗中的应用效果观察. 基层医学论坛, 2014,18(29): 3960-3961.
7. 聂红霞, 刘叶娟, 唐伟敬. 新辅助化疗方案在乳腺癌治疗中的应用效果观察. 当代医学, 2013, 19(5): 48-49.
8. 张莉. 新辅助化疗方案在乳腺癌治疗中的应用效果观察. 中外医学研究, 2014, 12(2): 116-117.
9. 陈丽娟. 新辅助化疗方案TE与FEC治疗局部晚期乳腺癌疗效观察. 中国医药指南, 2011, 9(28): 214-216.
10. 邹玉峰. 局部晚期乳腺癌新辅助化疗的研究. 中国当代医药, 2016, 23(32): 65-67.
11. 郑慧. 表阿霉素联合紫杉醇在局部晚期乳腺癌新辅助化疗治疗中的疗效评价. 中国实用医药, 2014, 9(21): 111-112.
12. 刘一范. 表阿霉素联合紫杉醇新辅助化疗治疗局部晚期乳腺癌疗效分析. 临床合理用药杂志, 2014, 7(19): 60-61.
13. 刘宏军, 杨德启, 曹迎明, 等. 不同新辅助化疗方案治疗乳腺癌的临床观察. 中国肿瘤临床, 2004, 31 (16): 31-34.
14. 贾琦. 两种新辅助化疗方案治疗乳腺癌的近期疗效和不良反应比较. 哈尔滨医药, 2012, 32(3): 196-197.
15. 王冰涛, 马向涛, 姚金华, 等. 术前ET与CEF新辅助化疗方案治疗乳腺癌的临床观察. 北京医学, 2007, 29(11): 658-660.
16. 韩瑜. 表阿霉素联合紫杉醇在局部晚期乳腺癌新辅助化疗治疗中的临床疗效分析. 中国伤残医学, 2013, 21(9): 162-163.
17. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol, 2005, 16(10): 1569-1583.
18. 陈灿铭, 沈坤炜, 吴炅, 等. 去甲长春花碱加表柔比星新辅助化疗方案治疗局部晚期乳腺癌的临床研究. 中国癌症杂志, 2003, 13(4): 28-31.
19. Crown J, O'Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical. Oncologist, 2004, 9(Suppl 2): 24-32.
20. Andrade JM, Carrara HH , Pimentel FF, et al. Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer. Med Oncol, 2011, 28(Suppl 1): 65-69.
21. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol, 2008, 26(1): 44-53.
22. 武阳. 表阿霉素联合紫杉醇在局部晚期乳腺癌新辅助化疗中的应用观察. 中国实用医药, 2014, 9(24): 155-156.

Chinese Journal of Evidence-Based Medicine

Efficacy and safety of TE regimen versus CEF regimen for Chinese women with TNM ⅡA to ⅢC stage breast cancer: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content